University School of Management and Entrepreneurship, Delhi Technological University, Vivek Vihar-Phase II, Delhi, 110095, India.
Breast Cancer. 2019 Jul;26(4):428-445. doi: 10.1007/s12282-018-00941-4. Epub 2019 Jan 2.
To examine breast cancer burden in females using incidence, mortality and mortality-to-incidence ratio (MIR) and its association with human development.
We employ the data of breast cancer in females from the Global Burden of Disease 2016 study for the period 1990 to 2016 for 102 countries. Human development is measured using the human development index (HDI). 5-year survival rate of breast cancer is proxied using the mortality-to-incidence ratio (MIR).
Globally, breast cancer has claimed 535341 female lives and 1.7 million incident cases had surfaced in 2016. High incidence rates were observed in very high HDI countries led by the Netherlands (117.2/100,000), whereas the mortality rate was high in low/medium HDI countries led by Afghanistan (35.4/100,000). Breast cancer incidence has more than doubled in 60/102 countries, whereas deaths have doubled in 43/102 countries. Globally, breast cancer MIR decreased from 0.41 to 0.32 over 1990-2016 and displayed negative gradient with HDI (r = - 0.87), indicating a low 5-year survival in less developed countries.
Heterogeneity in breast cancer burden, as per human development, and increasing breast cancer incidence and low survival rates, indicated by MIR, call for broader human development, improving breast cancer awareness, and cost-effective screening and treatment in less developed countries.
利用发病率、死亡率和死亡率与发病率比(MIR)来研究女性乳腺癌负担,并探讨其与人类发展的关系。
我们使用了 2016 年全球疾病负担研究中 1990 年至 2016 年期间 102 个国家女性乳腺癌的数据。人类发展用人类发展指数(HDI)衡量。乳腺癌 5 年生存率用死亡率与发病率比(MIR)来表示。
全球范围内,2016 年乳腺癌导致 535341 名女性死亡,新发病例达 170 万例。荷兰等极高人类发展指数国家的发病率较高(117.2/100000),而阿富汗等低/中人类发展指数国家的死亡率较高(35.4/100000)。60/102 个国家的乳腺癌发病率增加了一倍以上,43/102 个国家的死亡率增加了一倍以上。全球范围内,乳腺癌 MIR 从 1990 年至 2016 年从 0.41 降至 0.32,与 HDI 呈负相关(r=-0.87),这表明欠发达国家的乳腺癌 5 年生存率较低。
乳腺癌负担在人类发展方面存在异质性,而且 MIR 显示发病率不断增加和生存率较低,这需要在欠发达国家进一步促进人类发展,提高对乳腺癌的认识,并实施具有成本效益的筛查和治疗。